Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  Pharming  /  Valeant draadje

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

  • 0,900 26 apr 2024 17:35
  • +0,019 (+2,16%) Dagrange 0,883 - 0,903
  • 3.641.122 Gem. (3M) 6,8M

Valeant draadje

353 Posts
Pagina: «« 1 ... 10 11 12 13 14 ... 18 »» | Laatste | Omlaag ↓
  1. [verwijderd] 1 juli 2016 15:14
    AstraZeneca inks deal with Leo Pharma for dermatology meds tralokinumab and brodalumab

    Jul 1 2016, 08:25 ET | About: AstraZeneca Group plc (AZN) | By: Mamta Mayani,

    AstraZeneca (NYSE:AZN) enters into an agreement with privately held Danish drug firm LEO Pharma for a global licence to tralokinumab and European rights to brodalumab.

    Under the terms of the agreement, LEO Pharma will make an upfront payment to AstraZeneca of $115M for the exclusive, global rights to tralokinumab for skin diseases. It will also pay AstraZeneca up to $1B in commercially-related milestones and royalties on product sales.

    AstraZeneca reacquired the European rights to brodalumab from Valeant Pharmaceuticals (NYSE:VRX), who will continue to lead development and commercialization in the U.S. and other markets not covered by Kyowa Hakko Kirin (Japan and certain other Asian countries). LEO Pharma acquired the European rights under similar terms as Valeant, including paying a low single-digit royalty to AstraZeneca.

    Tralokinumab is a potential new medicine (an anti-IL-13 monoclonal antibody) that has completed a Phase IIb trial for the treatment of patients with atopic dermatitis, an inflammatory skin disease resulting in itchy, red, swollen and cracked skin.
    Brodalumab is an IL-17 receptor monoclonal antibody under regulatory review for patients with moderate-to-severe plaque psoriasis and in development for psoriatic arthritis.
    The tralokinumab deal should be completed in Q3. The brodalumab deal was effective at signing. Neither will impact AstraZeneca's financial guidance for this year.

    ===============

    -Aardig om 2 redenen:

    -Valeant stoot een stukje sales in Europa af

    -LEOPharma kennen we nog als het bedrijf dat samen met GTCB, het "zusterbedrijf" van Pharming, een preparaat ontwikkelde met behulp van de transgene technologie maar plotsklaps de samenwerking opzegde.
  3. [verwijderd] 7 juli 2016 20:08


    Valeant Pharmaceuticals Intl Inc (NYSE:VRX): Second Published Phase 3 Trial Demonstrates Greater Efficacy

    Valeant Pharmaceuticals Intl Inc (NYSE:VRX): Second Published Phase 3 Trial Demonstrates Greater Efficacy





    Companies owned by the Canadian pharmaceutical giant announced the publication of latanoprostene bunod phase 3 study results called LUNAR

    Published By: Angela Campbell on July 7, 2016 08:17 am EST

    Bausch + Lomb and Nicox S.A., the wholly owned subsidiaries of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced yesterday that the American Journal of Ophthalmology has published results of latanoprostene bunod ophthalmic solution 0.024%, which is in the third phase of study. The once daily eye drop is for patients suffering from ocular hypertension and open angle glaucoma.




    The results published are the second results of phase 3 trial study that demonstrate its greater effectiveness relative to Timolol Maleate 0.5%. The ophthalmic solution is a single agent eye drop that lowers intraocular pressure by increasing aqueous humor outflow through uveoscleral routes and trabecular meshwork. The phase 3 study results, known as LUNAR, were found superior when compared with Timolol Maleate 0.5% as it provided greater and rapid IOP reduction. Also, the LBN drop is directed once daily whereas the Timolol Maleate is dosed twice daily in patients suffering from OAG and OHT.

    Robert N. Weinreb, Chairman and Professor at the University of California said that he recently published results of second phase 3 study reveal LBN’s efficiency to lower IOP better than others and if the FDA approves of it, the ophthalmic solution would provide as an innovative alternative to treat the patients susceptible to OHT and OAG.

    Bausch + Lomb, the eye care division of Valeant, submitted an application to the FDA, Food & Drug Administration in July 2015. The application was accepted by FDA and the administration has said to complete the application review by July 21, 2016 under the Prescription Drug User Fee Act. If the FDA approves of the LBN, it will become the first available analog drug for the indication of nitric oxide donating prostaglandin F2a.




    Meanwhile, the data on Thomson Reuters reveal that the consensus has positioned their 12-month average price target on Valeant’s stock at $42.89. The figure reflects a optimistic potential upside of 85.99% over the last close of $23.06.

    www.thecountrycaller.com/19040-valean...

  6. [verwijderd] 9 juli 2016 15:00
    quote:

    Wishdom schreef op 9 juli 2016 14:53:

    Leuk leesvoer.

    Valeant Is 'The Walking Dead'

    The troubled drugmaker will have to perform a careful balancing act it begins to unwind some of its businesses to shore up cash.

    www.thestreet.com/story/13632476/1/va...

    Vertel er ook even bij diegene die dit schrijft een short seller is :)

    #mediahypes
  11. [verwijderd] 13 juli 2016 16:36


    3 Prime Reasons Why Valeant Pharmaceuticals Intl. Inc. Plunged 29% in June

    Valeant's woes continue to build -- is there an end in sight?

    Lab Research Biotech Dropper Into Test Tube Getty
    Image source: Getty Images.

    What: Shares of Valeant Pharmaceuticals (NYSE:VRX), a diversified pharmaceutical company that's primarily used mergers and acquisitions to grow its business, plummeted 29% in June, based on data from S&P Global Market Intelligence. There appear to be three prime culprits behind Valeant's June swoon.

    So what: The first issue, which stuck out as a sore thumb to Valeant shareholders, related to the company's first-quarter earnings report (which was filed late). Valeant, coming off a sour deal and $58 million in improperly booked revenue with now-former drug distributor Philidor Rx Services, forged a 20-year drug distribution contract with Walgreens Boots Alliance (NASDAQ:WBA).

    Unfortunately, we observed in its Q1 report that the early stages of this deal have been filled with potholes and bumps for Valeant. Drugs are being reimbursed at rates too low for Valeant to be profitable in some instances, while reimbursements are simply taking too long in other cases. For what it's worth, Walgreens is committed to making its long-term deal with Valeant work, but it doesn't look as if Valeant's distribution woes will be resolved overnight.

    Secondly, and also relating to Valeant's Q1 report, the company slashed its full-year guidance, once again. The latest guidance for fiscal 2016 calls for a midpoint of $10 billion in sales, and $6.80 in EPS. By comparison, Valeant's fiscal 2016 midpoints for sales and EPS were $11.1 billion and $9, respectively, in mid-March, and $12.6 billion and $13.50, respectively, in mid-December 2015. With estimates plunging, shareholders have no idea where the bottom is.

    Finally, Wall Street pundits continue to be hypercritical of Valeant's $31.3 billion debt load, which has cut off the company's access to further credit following its recent EBIDTA reductions. Analysts have suggested that Valeant's only recourse may be to sell some of its core assets to reduce its debt. Doing so could crush the company's growth potential moving forward.


    Money Under Chain And Lock Debt Getty
    Image source: Getty Images.

    Now what: Although July has brought a little bit of relief for Valeant shareholders, I wouldn't, by any means, consider this company out of the woods.

    The biggest issue for Valeant, in my opinion, is its debt. If the company doesn't sell enough assets, its debt will constrain its ability to make strategic moves. If, however, Valeant gets rid of its core assets and reduces its debt load by 50% to 75%, its remaining assets may not present attractive enough growth prospects to push its share price higher. Worse yet, Valeant could struggle to get anywhere near a fair value for its assets, given its distressed status.

    Another debt issue is its debt covenants. Valeant's lenders attached certain "requirements," known as covenants, to Valeant's debt to ensure their loan remains safe. One of these covenants is that Valeant's EBITDA remains at least 2.75 times higher, on an annual basis, than its interest costs on its debt. Valeant is getting dangerously close to breaching this figure, which could, once again, trigger a debt default.

    There are no clear answers as to how Valeant will right the ship, and I'd personally suggest sticking to the sidelines until we get more clarity on Valeant's pricing practices, as well as how it will handle reducing its debt.

    Has Valeant Pharmaceuticals tripled the market's return over the last decade?
    Because that's exactly what David and Tom's Gardner's stock picks have done over the last 13 years in Motley Fool Stock Advisor. And they're going to release their newest picks this Friday at noon.

    www.fool.com/investing/2016/07/13/3-p...
  13. [verwijderd] 22 juli 2016 13:44
    Valeant receives CRL in response to latanoprostene NDA

    Valeant Pharmaceuticals' (NYSE:VRX) Bausch + Lomb unit receives a Complete Response Letter (CRL) regarding its New Drug Application (NDA) seeking approval of latanoprostene bunod ophthalmic solution, 0.024%, an intraocular pressure-lowering single-agent eye drop for patients with open angle glaucoma or ocular hypertension.

    The CRL cited deficiencies observed during a Current Good Manufacturing Practice (CGMP) inspection at B+L's manufacturing site in Tampa, FL. The letter did not identify any safety or efficacy issues with the product.Valeant intends to meet with the agency as soon as possible to address the matter.

    VRX is down 2% premarket on light volume.

    +++++++++++++++++++++++++++++++++++++++++

    Uiterst slordig van Valeant/B&L in de huidige omstandigheden! Betekent vertraging goedkeuring.
353 Posts
Pagina: «« 1 ... 10 11 12 13 14 ... 18 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Premium

Logische herfinanciering Pharming

Het laatste advies leest u als abonnee van IEX Premium

Inloggen Word Abonnee

Pharming Nieuws

  1. 19 apr Pharming lost voor 123 miljoen euro aan obligaties af
  2. 18 apr Pharming rondt plaatsing obligaties af 5
  3. 18 apr Pharming vervangt converteerbare lening 6
  4. 08 apr Pharming rondt rekrutering voor klinische studie leniolisib met kinderen af
  5. 14 mrt CEO: Pharming haalt omzet uit steeds meer landen 2
  6. 14 mrt Lichte plus voor AEX voorzien; zullen Pharming en Basic-Fit de boel opschudden?
  7. 14 mrt Pharming rekent ook voor 2024 op dubbelcijferige omzetgroei 2
  8. 13 mrt Slotcall: Twijfel slaat toe bij chippers, AEX sluit iets lager na wispelturige sessie
  9. 11 mrt Beursblik: hogere jaaromzet Pharming verwacht
  10. 11 mrt AEX gaat opnieuw rode opening tegemoet, Japan ontloopt recessie maar Nikkei duikelt 1

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!